In the Claims:

Please cancel claims 1-30 without prejudice to continued prosecution. Please add new claims 31- 60. The claims and their status are shown below.

1-30. (Canceled)

31. (New) A medicament for tumor therapy, comprising an effective concentration of a first and a second molecule,

wherein the first molecule is Annexin V, a fragment thereof having functional Annexin V activity, or a polypeptide having at least 80% sequence identity to Annexin V and having functional Annexin V activity,

wherein the second molecule is a cytokine, a fragment thereof having functional cytokine activity, or a polypeptide having at least 80% sequence identity to a cytokine and having functional cytokine activity.

32. (New) The medicament of claim 31, wherein the Annexin V has at least 85% sequence identity with SEQ ID NO: 1 or 2.

33. (New) The medicament of claim 31, wherein the Annexin V has at least 90% sequence identity with SEQ ID NO: 1 or 2.

34. (New) The medicament of claim 31, wherein the Annexin V has at least 95% sequence identity with SEQ ID NO: 1 or 2.

35. (New) The medicament of claim 31, wherein the Annexin V has the sequence shown in SEQ ID NO: 1 or 2.

36. (New) The medicament of claim 31, wherein the Annexin V is a non-human Annexin V.

37. (New) The medicament of claim 36, wherein the non-human Annexin V is a chicken Annexin V.

38. (New) The medicament of claim 31, wherein the cytokine is selected from the group consisting of Interleucine-2, Interleucine-6, Interleucine-7, Interleucine-12, GM-CSF, TNF-α, and IL-1β.

39. (New) The medicament of claim 31, wherein one unit of administration comprises 0.05 to 0.5 $mg/g_{Tumorweight}$ of the first molecule.

40. (New) The medicament of claim 31, wherein one unit of administration comprises 0.1 to 2.5 mg of the first molecule.

41. (New) The medicament of claim 40, wherein one unit of administration comprises 0.5 to 2.0 mg of the first molecule.

42. (New) The medicament of claim 31, wherein one unit of administration comprises 50,000 to 1,000,000 International Units of the second molecule.

43. (New) The medicament of claim 42, wherein one unit of administration comprises 300,000 to 750,000 International Units of the second molecule.

44. (New) The medicament of claim 31, wherein the medicament is formulated as an injectable fluid.

45. (New) The medicament of claim 44, wherein the medicament is formulated in a buffered saline solution.

46. (New) The medicament of claim 31, wherein one unit of administration comprises 0.5 to 50 ml.

47. (New) The medicament of claim 46, wherein one unit of administration comprises 1 to 10 ml.

48. (New) The medicament of claim 31, further comprising apoptotic and/or necrotic tumor cells.

49. (New) The medicament of claim 48, wherein the tumor cells are human tumor cells.

50. (New) The medicament of claim 48, wherein the tumor cells are in contact with the first and second molecule.

51. (New) A method of reducing the mass of a tumor, comprising:

contacting the tumor with the medicament of claim 31.

52. (New) The method of claim 51, further comprising the step of monitoring the tumor for a reduction in mass.

53. (New) The method of claim 51, wherein the tumor is a tumor effusion.

54. (New) The method of claim 51, wherein the tumor is a mamma carcinoma.

55. (New) The method of claim 51, wherein the medicament is injected into the tumor.

56. (New) The method of claim 55, wherein the volume of the medicament injected is 0.5 to 50 ml.

57. (New) The method of claim 56, wherein the volume of the medicament injected is 1 to 10 ml.

58. (New) The method of claim 51, wherein the medicament further comprises apoptotic and/or necrotic tumor cells.

59. (New) The method of claim 51, wherein the tumor cells are human tumor cells.

60. (New) The method of claim 51, wherein the tumor cells are apoptotic and/or necrotic tumor cells from the contacted tumor.

Amended Claims

1. Medicament for tumor therapy during which a first and a second molecule are contained in an effective concentration, wherein the first molecule is

a1) Annexin V or a molecule which is largely similar thereto,

or

a2) an effective fragment of Annexin V or the molecule which is largely similar thereto,

wherein the amino acid sequence of the first molecule corresponds to the amino acid sequence of the SEQ ID no. 1 or no. 2 or is at least 50% identical thereto,

and wherein the second molecule is

b1) a cytokine or a molecule which is largely similar thereto

or

b2) an effective fragment of a cytokine or the molecule which is largely similar thereto.

2. Medicament as defined in claim 1, wherein the amino acid sequence of the first molecule is identical to the amino acid sequence of SEQ ID no. 1 or no. 2 by at least 60%, preferably by at least 70%, particularly preferably by at least 80%.

3. Medicament as defined in one of the preceding claims, wherein the Annexin V is a non-human Annexin V.

4. Medicament as defined in one of the preceding claims, wherein the non-human Annexin V is the Annexin V of the chicken.

5. Medicament as defined in one of the preceding claims, wherein the cytokine is selected from the following group: Interleucine-2, Interleucine-6, Interleucine-7, Interleucine-12, GM-CSF, TNF-α, IL-1β.

6. Medicament as defined in one of the preceding claims, wherein 0.05 to 0.5 $mg/g_{Tumorweight}$ on the first molecule are contained in one unit of administration.

7. Medicament as defined in one of the preceding claims, wherein one unit of administration contains 0.1 to 2.5 mg, preferably 0.5 to 2.0 mg on the first molecule.

8. Medicament as defined in one of the preceding claims, wherein one unit of administration contains 50,000 to 1,000,000 International Units, preferably 300,000 to 750,000 International Units on the second molecule.

9. Medicament as defined in one of the preceding claims, wherein the first and the second molecule are held in an injection fluid, preferably in a buffered saline solution.

10. Medicament as defined in one of the preceding claims, wherein the volume of the injection fluid is 0.5 to 50 ml, preferably 1 to 10 ml.

11. Medicament as defined in one of the preceding claims, wherein it includes apoptotic and/or necrotic tumor cells.

12. Medicament as defined in one of the preceding claims, wherein it further includes human tumor cells.

13. Medicament as defined in one of the preceding claims, wherein the tumor cells are apoptotic and/or necrotic tumor cells of the tumor to be treated.

14. Medicament as defined in one of the preceding claims, wherein the tumor cells are in contact with the protein.

15. Use of a first molecule, namely

a1) Annexin V or a molecule which is largely similar thereto

or

a2) an effective fragment of Annexin V or the molecule which is largely similar thereto,

wherein the amino acid sequence of the first molecule corresponds to the amino acid sequence of the SEQ ID no. 1 or no. 2 or is at least 50% identical thereto,

in combination with a second molecule, namely

b1) a cytokine or a molecule which is largely similar thereto

or

b2) an effective fragment of a cytokine or the molecule which is largely similar thereto,

for tumor therapy.

16. Use as defined in claim 15, wherein the tumor is a tumor effusion.

17. Use as defined in claim 15 or 16, wherein the tumor is a mamma carcinoma.

18. Use as defined in one of the claims 15 to 17, wherein the amino acid sequence of the first molecule is identical to the amino acid sequence of SEQ ID no. 1 or no. 2 by at least 60% thereto, preferably by at least 70%, particularly preferably by at least 80%.

19. Use as defined in one of the claims 15 to 18, wherein the Annexin V is non-human Annexin V.

20. Use as defined in one of the claims 15 to 19 wherein the non-human Annexin V is the Annexin V of the chicken.

21. Use as defined in one of the claims 15 to 20, wherein the cytokine is selected from the following group: Interleucine-2, Interleucine-6, Interleucine-7, Interleucine-12, GM-CSF, TNF-α, IL-1β.

22. Use as defined in one of the claims 15 to 21, wherein one administration unit contains 0.05 to 0.5 $mg/g_{Tumorweight}$ on the first molecule.

23. Use as defined in one of the claims 15 to 22, wherein one unit of administration contains 0.1 to 2.5 mg, preferably 0.5 to 2.0 mg on the first molecule.

24. Use as defined in one of the claims 15 to 23, wherein one unit of administration contains 50,000 to 1,000,000 International Units, preferably 300,000 to 750,000 International on the second molecule.

25. Use as defined in one of the claims 15 to 24, wherein the first and the second molecule are contained in an injection fluid, preferably in a buffered saline solution.

26. Use as defined in one of the claims 15 to 25, wherein the volume of the injection fluid is 0.5 to 50 ml, preferably 1 to 10 ml.

27. Use as defined in one of the claims 15 to 26, wherein it includes apoptotic and/or necrotic tumor cells.

28. Use as defined in one of the claims 15 to 27, wherein it further includes human tumor cells.

29. Use as defined in one of the claims 15 to 28, wherein the tumor cells are apoptotic and/or necrotic tumor cells of the tumor to be treated.

30. Use as defined in one of the claims 15 to 29, wherein the tumor cells are in contact with the protein.